Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
36 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014', provides an overview of the Hormone-Sensitive Prostate Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hormone-Sensitive Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone-Sensitive Prostate Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hormone-Sensitive Prostate Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hormone-Sensitive Prostate Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hormone-Sensitive Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hormone-Sensitive Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hormone-Sensitive Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hormone-Sensitive Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hormone-Sensitive Prostate Cancer Overview 6 Therapeutics Development 7 Pipeline Products for Hormone-Sensitive Prostate Cancer - Overview 7 Pipeline Products for Hormone-Sensitive Prostate Cancer - Comparative Analysis 8 Hormone-Sensitive Prostate Cancer - Therapeutics under Development by Companies 9 Hormone-Sensitive Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 10 Hormone-Sensitive Prostate Cancer - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Hormone-Sensitive Prostate Cancer - Products under Development by Companies 13 Hormone-Sensitive Prostate Cancer - Products under Investigation by Universities/Institutes 14 Hormone-Sensitive Prostate Cancer - Companies Involved in Therapeutics Development 15 Ipsen S.A. 15 Ultimovacs AS 16 Hormone-Sensitive Prostate Cancer - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 Peptide Based Therapeutic Cancer Vaccine - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Vaccine to Target Prostate Specific Antigen for Hormone-Sensitive Prostate Cancer - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 STX-2171 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 MVI-118 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecules to Inhibit AKR1C3 for Oncology - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Hormone-Sensitive Prostate Cancer - Recent Pipeline Updates 31 Hormone-Sensitive Prostate Cancer - Dormant Projects 32 Hormone-Sensitive Prostate Cancer - Discontinued Products 33 Hormone-Sensitive Prostate Cancer - Product Development Milestones 34 Featured News & Press Releases 34 Apr 15, 2014: UK NICE guidance recommends FIRMAGON (degarelix) for the treatment of advanced hormone-dependent prostate cancer only in people with spinal metastases who present with signs or symptoms of impending spinal cord compression 34 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 35 Contact Us 36 Disclaimer 36
List of Tables Number of Products under Development for Hormone-Sensitive Prostate Cancer, H2 2014 7 Number of Products under Development for Hormone-Sensitive Prostate Cancer - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Hormone-Sensitive Prostate Cancer - Pipeline by Ipsen S.A., H2 2014 15 Hormone-Sensitive Prostate Cancer - Pipeline by Ultimovacs AS, H2 2014 16 Assessment by Monotherapy Products, H2 2014 17 Number of Products by Stage and Target, H2 2014 19 Number of Products by Stage and Mechanism of Action, H2 2014 21 Number of Products by Stage and Route of Administration, H2 2014 23 Number of Products by Stage and Molecule Type, H2 2014 25 Hormone-Sensitive Prostate Cancer Therapeutics - Recent Pipeline Updates, H2 2014 31 Hormone-Sensitive Prostate Cancer - Dormant Projects, H2 2014 32 Hormone-Sensitive Prostate Cancer - Discontinued Products, H2 2014 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.